Rise and shine, another busy day is on the way. We can tell because the short person has emerged to get a jump on schoolwork due in a few weeks and the official mascot is noisily bounding about the official Pharmalot grounds. As for us, we are watching our to-do list lengthen and trying to keep track of Zoom calls. Perhaps you can relate. Meanwhile, time for another cup of stimulation. Our choice today is maple bourbon. And of course, here are a few tidbits to get you going. Hope all goes well today, and do keep in touch. One more thing, wear a mask. …

Given the prevailing business-centric model of American drug pricing, a Covid-19 vaccine could well be budget-breaking, perhaps making it unavailable to many, Kaiser Health News writes. The concern emerges at a time when drug development is one of the world’s most lucrative businesses, ownership of drug patents is disputed in endless court battles, and monopoly power often lets manufacturers set any price, no matter how extraordinary — and the American government has no effective way to fight back.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy